Alnylam to Host Sixth Annual “RNAi Roundtable” Webcast Series
September 06 2019 - 7:30AM
Business Wire
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi
therapeutics company, announced today that it plans to kick off its
6th annual series of “RNAi Roundtable” webcasts over the coming
weeks. The series will offer a range of presentations from Alnylam
scientists and program leaders, clinical collaborators, and
patients or patient advocates, who will review recent progress in
many of the Company’s late-stage pipeline programs and platform.
Each event will be webcast live on the Investors page of the
Company’s website, www.alnylam.com, and a replay of the roundtables
will be posted on the Alnylam website approximately three hours
after each event.
The initial RNAi Roundtable schedule will be as follows:
- Patisiran & Vutrisiran, for the Treatment of
Transthyretin-Mediated Amyloidosis Monday, September 16, 1:00
pm ET
- Givosiran, in Development for the Treatment of Acute Hepatic
Porphyria Monday, October 7, 9:30 am ET
- Lumasiran, in Development for the Treatment of Primary
Hyperoxaluria Type 1 Thursday, October 10, 11:30 am ET
Please visit the Capella section of our website for the latest
information regarding webcast schedules.
About RNAi RNAi (RNA interference) is a natural cellular
process of gene silencing that represents one of the most promising
and rapidly advancing frontiers in biology and drug development
today. Its discovery has been heralded as “a major scientific
breakthrough that happens once every decade or so,” and was
recognized with the award of the 2006 Nobel Prize for Physiology or
Medicine. By harnessing the natural biological process of RNAi
occurring in our cells, a new class of medicines, known as RNAi
therapeutics, is now a reality. Small interfering RNA (siRNA), the
molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic
platform, function upstream of today’s medicines by potently
silencing messenger RNA (mRNA) – the genetic precursors – that
encode for disease-causing proteins, thus preventing them from
being made. This is a revolutionary approach with the potential to
transform the care of patients with genetic and other diseases.
About Alnylam Pharmaceuticals Alnylam (Nasdaq: ALNY) is
leading the translation of RNA interference (RNAi) into a new class
of innovative medicines with the potential to transform the lives
of people afflicted with rare genetic, cardio-metabolic, hepatic
infectious, and central nervous system/ocular diseases. Based on
Nobel Prize-winning science, RNAi therapeutics represent a
powerful, clinically validated approach for the treatment of
diseases with high unmet need. Alnylam’s first commercial RNAi
therapeutic is ONPATTRO® (patisiran), approved in the U.S., EU,
Canada, and Japan. Alnylam has a deep pipeline of investigational
medicines, including five product candidates in Phase 3 studies and
one in registration. Looking forward, Alnylam will continue to
execute on its “Alnylam 2020” strategy of building a multi-product,
commercial-stage biopharmaceutical company with a sustainable
pipeline of RNAi-based medicines to address the needs of patients
who have limited or inadequate treatment options. Headquartered in
Cambridge, MA, Alnylam employs over 1,200 people worldwide. For
more information about our people, science and pipeline, please
visit www.alnylam.com and engage with us on Twitter at @Alnylam or
on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190906005067/en/
Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom
(Investors and Media) 617-682-4340
Josh Brodsky (Investors) 617-551-8276
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Apr 2023 to Apr 2024